Kvasnicka, H M <br/><br/>
Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jun 2001 
 - 2994-3009 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2001.19.12.2994  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Bone Marrow--pathology<br/>Decision Trees<br/>Female<br/>Humans<br/>Hydroxyurea--therapeutic use<br/>Interferon alpha-2<br/>Interferon-alpha--therapeutic use<br/>Leukemia, Myeloid, Chronic-Phase--classification<br/>Lymphocyte Activation<br/>Macrophages--pathology<br/>Male<br/>Megakaryocytes--pathology<br/>Middle Aged<br/>Multivariate Analysis<br/>Primary Myelofibrosis--pathology<br/>Prognosis<br/>Recombinant Proteins<br/>Regression Analysis<br/>Reproducibility of Results<br/>Risk<br/>Sensitivity and Specificity<br/>Survival Analysis